SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 6 — Focused Visit (Care-plan review) — Diana, Princess of Wales

PatientDiana Spencer
Date of birth1997-07-01
IdentifiersMRN HR-ML028-SYN; SSN (made up) 000-28-5197
Document date2026-07-13
AuthorImogen Castleford, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

End-of-treatment review after 20 weeks of CBT-E. [S]

History of Present Illness

Ms. Spencer returns at the end of CBT-E; she had her twentieth session last week and has a written relapse-prevention plan with her own early warning signs (skipping meals, a run of long days, and feeling low) and what to do about each. She has had no binge eating or vomiting for six weeks. She eats three meals and two snacks every day and no longer weighs herself daily. Her end-of-treatment EDE-Q global score is 1.6. She takes fluoxetine 60 mg each morning without side effects. Her mood is good, she sleeps well, and she has had no thoughts of suicide or self-harm. She has told two close friends about her treatment. [S]

ElementDetail
Binge eating and vomitingNone for six weeks
CBT-ECompleted 20 sessions; written relapse-prevention plan
EDE-Q global score1.6
MoodGood; PHQ-9 4; item 9 scored 0

Review of Systems

SystemResultFinding
ConstitutionalNegativeEnergy good; weight steady
GastrointestinalNegativeNo vomiting for six weeks
Ears, nose, mouth, and throatNegativeNo tooth sensitivity
PsychiatricNegativeMood good; no thoughts of suicide or self-harm

4 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Potassium chloride 20 mEq extended-release oral tablet, one tablet by mouth twice daily with foodOne tablet by mouth twice daily with food, swallowed whole with a full glass of waterOral route2026-02-09 to 2026-03-16completedS
Fluoxetine 20 mg oral capsule, one capsule by mouth each morning for one week, then two capsules each morning for one weekOne capsule each morning for one week, then two capsules each morning for one weekOral route2026-02-16 to 2026-03-02completedS
Fluoxetine 60 mg oral tablet, one tablet by mouth each morningOne tablet by mouth each morningOral route2026-03-02activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-07-13Body height178cmS
2026-07-13Body weight62.1kgS
2026-07-13Body mass index (BMI) [Ratio]19.6kg/m2S
2026-07-13Systolic blood pressure108mm[Hg]S
2026-07-13Diastolic blood pressure68mm[Hg]S
2026-07-13Heart rate66/minS
2026-07-13Respiratory rate14/minS
2026-07-13Body temperature36.5CelS
2026-07-13Oxygen saturation in Arterial blood by Pulse oximetry99%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-07-13Sodium [Moles/volume] in Serum or Plasma140mmol/L135-145 mmol/LNormalS
2026-07-13Potassium [Moles/volume] in Serum or Plasma4.2mmol/L3.5-5.1 mmol/LNormalS
2026-07-13Chloride [Moles/volume] in Serum or Plasma103mmol/L98-107 mmol/LNormalS
2026-07-13Carbon dioxide, total [Moles/volume] in Serum or Plasma25mmol/L22-29 mmol/LNormalS
2026-07-13Creatinine [Mass/volume] in Serum or Plasma0.8mg/dL0.59-1.04 mg/dLNormalS
2026-07-13Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M102mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
2026-07-13Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]4{score}S

Physical Exam

Vital signs recorded on 2026-07-13; see the Vital Signs section. [S]

SystemFinding
GeneralWell; weight 62.1 kg, BMI 19.6; lying blood pressure 108/68 and pulse 66, standing 108/70 and pulse 72 after three minutes
Head and neckParotid glands normal in size; enamel erosion stable
PsychiatricBright and engaged; organized

Problems

ProblemClinical statusVerificationCodeProvenance
Bulimia nervosa, severe: recurrent binge eating, each time with self-induced vomiting, averaging about ten episodes a week for about three years, hidden from everyone; self-worth tied closely to body shape and weight; no laxatives, diuretics, diet pills, or excessive exercise. SCOFF 4 of 5; EDE-Q global score 3.9. Findings: bilateral parotid enlargement, enamel erosion on the inner surfaces of the upper front teeth, calluses on the backs of two knuckles of the right hand, a pulse rise of 22 per minute on standing, low potassium and chloride with a raised bicarbonate, and a raised amylase; BMI 19.3. Synthetic modern episode linked to her own public account of bulimiaactiveconfirmed F50.23S — Synthetic modern diagnosis by DSM-5-TR criteria; severity is graded by the average number of compensatory episodes a week (8 to 13 is severe).
Hypokalemia (potassium 3.1 mmol/L) with low chloride and metabolic alkalosis from repeated vomiting; QTc 452 ms; no palpitations, weakness, or faintingresolvedconfirmed E87.6S — Synthetic presenting laboratory finding; resolved when potassium was normal on two checks.
Major depressive disorder, recurrent, moderate: about two months of low mood, tiredness, poor sleep, and feeling worthless and hopeless, with little pleasure in things she used to enjoy; PHQ-9 14 with item 9 scored 0; an earlier episode of depression after childbirth. Synthetic modern episode linked to her own public account of depressionactiveconfirmed F33.1S — Synthetic modern diagnosis; the earlier episode is the post-natal depression she described publicly.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
SurveyBinge-eating and vomiting frequency (her self-monitoring record)Every visitCompleted todayNone for six weeks
SurveyEating Disorder Examination Questionnaire (EDE-Q) global scoreBaseline, mid-treatment, and end of treatmentCompleted todayGlobal score 1.6 at the end of treatment, from 3.9 at intake
ExaminationWeight and BMIEvery visit, and weekly in CBT-E sessionsCompleted today62.1 kg, BMI 19.6, steady through treatment
ExaminationLying and standing pulse and blood pressureEvery visit while purging continuesCompleted todayLying 108/68, pulse 66; standing 108/70, pulse 72 (rise 6)
LaboratoryPotassium, chloride, bicarbonate, and creatinineWeekly until potassium is normal twice, then at each medical visit while purging continuesCompleted todayPotassium 4.2 mmol/L; sodium 140, chloride 103, bicarbonate 25 mmol/L; creatinine 0.80 mg/dL, eGFR 102. Repeat only if vomiting returns
ExaminationParotid and dental examination; dental protectionEvery visit; a dental examination soon after diagnosis and regular dental reviews while vomiting continuesUp to dateErosion stable; dental review in about three months
Medication safetyFluoxetine dose, adherence, and side effects (nausea, sleep, agitation, sexual effects, suicidal thoughts)At the start, one to two weeks after starting or a dose change, then every visitCompleted today60 mg; no side effects; continue for at least a year after remission
Self-managementCBT-E attendance and progressUp to 20 sessions over 20 weeks, twice weekly for the first four weeksCompleted todayCompleted 20 sessions; relapse-prevention plan written; booster sessions at one and three months
Self-managementRegular eating and dietitian reviewEvery visitCompleted todayThree meals and two snacks every day
SurveyDepression measure (PHQ-9)Monthly during acute treatment, then periodicallyCompleted todayPHQ-9 4, item 9 scored 0: remission
SurveySuicide-risk review, safety plan, lethal means, and the 988 Suicide & Crisis LifelineEvery visitCompleted todayNo thoughts of suicide or self-harm; safety plan and the 988 Suicide & Crisis Lifeline current

Goal progress:

Guideline basis: The American Psychiatric Association Practice Guideline for the Treatment of Patients With Eating Disorders, Fourth Edition (2023); Eating disorders: recognition and treatment (NICE guideline NG69) (2017, updated 2020); Depression and Suicide Risk in Adults: Screening (2023); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024); CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026)

Follow-up: Booster CBT-E sessions at one and three months. Visit in three months, sooner for any return of bingeing or vomiting. Psychiatry review of fluoxetine after a year of remission. [S]